Alteplase v.s. Trisodium Citrate and Infection and Obstruction Incidence of Permanent Tunneled Dialysis Catheters
The incidence of infection and obstruction of newly inserted permanent tunneled dialysis catheters in chronic hemodialysis patients with using alteplase or trisodium citrate as a locking solution after the middle hemodialysis procedure.
Pavlina Richtrova, MD, PhD
80 participants
Feb 1, 2012
Interventional
Conditions
Summary
The aim of the study is to test the hypothesis that the application of alteplasis as a locking solution for tunneled dialysis permanent catheter once a week will decrease the incidence of catheter related blood stream infection and will influence the incidence of catheter obstruction/malfunction.
Eligibility
Inclusion Criteria1
- Patients with end stage kidney disease and newly inserted permanent tunneled dialysis catheter. Dialysis prescription = 3 times a week. Agreement with the trial participation.
Exclusion Criteria7
- anticoagulation treatment INR more than 1.4
- platelets count less than 60x109/l
- catheter insertion in vena cava inferior region (femoral vein)
- catheter insertion by a guide-wire exchange procedure
- active pericarditis with pericardial effusion
- known allergy or intolerance to alteplase or trisodium
- citrate pregnancy or breast-feeding
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
1mg of alteplase per lumen as a locking solution for permanent tunneled dialysis catheter once a week during the whole interdialysis interval (between dialysis procedure No. 2 and 3). Alteplase (1mg/1ml) will be administred into each lumen initially and then follow by saline at a volume adequate to fill the entire luminal volume (declared by manufacturer on each lumen of catheter).
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12612000152820